ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cetylpyridinium

Also written as “Cetylpyridinium chloride”, “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash” and “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”.

Its studies are mostly in Gingivitis · Dental Plaque · Pharyngitis · Diabetes Mellitus, Type 2 · Onychomycosis, led by 7 companies.

Drug pageCetylpyridinium: every studyMany companies study it; this page follows only the 15 they lead. All 27 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 6, 201515 company-led studies, 4 open or runningNext primary completion: Dec 1, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Colgate Palmoliveits history only61 open or runningphase 4since Feb 6, 2015Jul 15, 2014Jan 2, 2028phase 4 · NCT07619729
Procter and Gambleits history only20 open or runningphase 4since Sep 29, 2025Feb 28, 2012none ahead
Sanofiits history only20 open or runningphase 3since May 27, 2008May 27, 2008none ahead
Valenta Pharm JSC22 open or runningphase 1since Feb 17, 2025Feb 17, 2025Dec 1, 2026phase 1 · NCT06859281
Angelini Pharmaits history only10 open or runningphase 1since Apr 27, 2018Apr 27, 2018none ahead
NanoBioits history only10 open or runningphase 2since Mar 26, 2007Mar 26, 2007none ahead
Suzhou Neologics Bioscienceits history only11 open or runningphase 1since May 25, 2023May 25, 2023none ahead

Also a collaborator on its studies: Cross Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Valenta Pharm JSC only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2025First studies: 2 phase 1 studies in PharyngitisFirst studyNCT06859281, NCT06857890

Ahead

  1. Dec 1, 2026Primary completion: phase 1 study in PharyngitisNCT06859281
  2. Dec 1, 2026Primary completion: phase 1 study in PharyngitisNCT06857890

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Valenta Pharm JSC leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859281Pharyngitis · Russia1RecruitingDec 1, 202624
NCT06857890Pharyngitis · Russia1RecruitingDec 1, 202624

How it is read

Names in the registry

  • “Cetylpyridinium chloride”, 2 entries
  • “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash”, 1 entry
  • “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”, 1 entry
  • “Cetylpyridinium Chloride, Zinc Lactate and Hyaluronic Acid Mouthwash”, 1 entry
  • “Cetylpyridinium Chloride (CPC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.